A Full-Service Contract Development and Manufacturing Organization (CDMO) is a company that provides comprehensive services across the entire drug development and manufacturing lifecycle, from early-stage development to commercial-scale production. These organizations offer a wide range of services to pharmaceutical and biotechnology companies, allowing them to outsource various aspects of drug development and manufacturing to external partners with specialized expertise and capabilities.
The global Full-Service CDMO market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Full-Service CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Full-Service CDMO market size and forecasts, in consumption value ($ Million), 2019-2030
Global Full-Service CDMO market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Full-Service CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Full-Service CDMO market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Full-Service CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Full-Service CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Full-Service CDMO market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Full-Service CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO
麻豆原创 segment by Application
Pharmaceutical Company
Biotechnology Company
麻豆原创 segment by players, this report covers
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Full-Service CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Full-Service CDMO, with revenue, gross margin, and global market share of Full-Service CDMO from 2019 to 2024.
Chapter 3, the Full-Service CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Full-Service CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Full-Service CDMO.
Chapter 13, to describe Full-Service CDMO research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Full-Service CDMO by Type
1.3.1 Overview: Global Full-Service CDMO 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Full-Service CDMO Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 API CDMO
1.3.4 FDF CDMO
1.3.5 Packaging CDMO
1.3.6 Clinical CDMO
1.4 Global Full-Service CDMO 麻豆原创 by Application
1.4.1 Overview: Global Full-Service CDMO 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Pharmaceutical Company
1.4.3 Biotechnology Company
1.5 Global Full-Service CDMO 麻豆原创 Size & Forecast
1.6 Global Full-Service CDMO 麻豆原创 Size and Forecast by Region
1.6.1 Global Full-Service CDMO 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Full-Service CDMO 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Full-Service CDMO 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Full-Service CDMO 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Full-Service CDMO 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Full-Service CDMO 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Full-Service CDMO 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Lonza
2.1.1 Lonza Details
2.1.2 Lonza Major Business
2.1.3 Lonza Full-Service CDMO Product and Solutions
2.1.4 Lonza Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Lonza Recent Developments and Future Plans
2.2 Catalent
2.2.1 Catalent Details
2.2.2 Catalent Major Business
2.2.3 Catalent Full-Service CDMO Product and Solutions
2.2.4 Catalent Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Catalent Recent Developments and Future Plans
2.3 Thermo Fisher Scientific
2.3.1 Thermo Fisher Scientific Details
2.3.2 Thermo Fisher Scientific Major Business
2.3.3 Thermo Fisher Scientific Full-Service CDMO Product and Solutions
2.3.4 Thermo Fisher Scientific Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.4 Samsung Biologics
2.4.1 Samsung Biologics Details
2.4.2 Samsung Biologics Major Business
2.4.3 Samsung Biologics Full-Service CDMO Product and Solutions
2.4.4 Samsung Biologics Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Samsung Biologics Recent Developments and Future Plans
2.5 Fareva
2.5.1 Fareva Details
2.5.2 Fareva Major Business
2.5.3 Fareva Full-Service CDMO Product and Solutions
2.5.4 Fareva Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Fareva Recent Developments and Future Plans
2.6 WuXi AppTech
2.6.1 WuXi AppTech Details
2.6.2 WuXi AppTech Major Business
2.6.3 WuXi AppTech Full-Service CDMO Product and Solutions
2.6.4 WuXi AppTech Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 WuXi AppTech Recent Developments and Future Plans
2.7 WuXi Biologics
2.7.1 WuXi Biologics Details
2.7.2 WuXi Biologics Major Business
2.7.3 WuXi Biologics Full-Service CDMO Product and Solutions
2.7.4 WuXi Biologics Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 WuXi Biologics Recent Developments and Future Plans
2.8 Siegfried
2.8.1 Siegfried Details
2.8.2 Siegfried Major Business
2.8.3 Siegfried Full-Service CDMO Product and Solutions
2.8.4 Siegfried Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Siegfried Recent Developments and Future Plans
2.9 FUJIFILM Diosynth Biotechnologies
2.9.1 FUJIFILM Diosynth Biotechnologies Details
2.9.2 FUJIFILM Diosynth Biotechnologies Major Business
2.9.3 FUJIFILM Diosynth Biotechnologies Full-Service CDMO Product and Solutions
2.9.4 FUJIFILM Diosynth Biotechnologies Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
2.10 Asymchem
2.10.1 Asymchem Details
2.10.2 Asymchem Major Business
2.10.3 Asymchem Full-Service CDMO Product and Solutions
2.10.4 Asymchem Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Asymchem Recent Developments and Future Plans
2.11 Pfizer CentreOne
2.11.1 Pfizer CentreOne Details
2.11.2 Pfizer CentreOne Major Business
2.11.3 Pfizer CentreOne Full-Service CDMO Product and Solutions
2.11.4 Pfizer CentreOne Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Pfizer CentreOne Recent Developments and Future Plans
2.12 Delpharm
2.12.1 Delpharm Details
2.12.2 Delpharm Major Business
2.12.3 Delpharm Full-Service CDMO Product and Solutions
2.12.4 Delpharm Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Delpharm Recent Developments and Future Plans
2.13 Recipharm
2.13.1 Recipharm Details
2.13.2 Recipharm Major Business
2.13.3 Recipharm Full-Service CDMO Product and Solutions
2.13.4 Recipharm Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Recipharm Recent Developments and Future Plans
2.14 AGC Pharma Chemicals
2.14.1 AGC Pharma Chemicals Details
2.14.2 AGC Pharma Chemicals Major Business
2.14.3 AGC Pharma Chemicals Full-Service CDMO Product and Solutions
2.14.4 AGC Pharma Chemicals Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 AGC Pharma Chemicals Recent Developments and Future Plans
2.15 Boehringer Ingelheim
2.15.1 Boehringer Ingelheim Details
2.15.2 Boehringer Ingelheim Major Business
2.15.3 Boehringer Ingelheim Full-Service CDMO Product and Solutions
2.15.4 Boehringer Ingelheim Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.15.5 Boehringer Ingelheim Recent Developments and Future Plans
2.16 Vetter
2.16.1 Vetter Details
2.16.2 Vetter Major Business
2.16.3 Vetter Full-Service CDMO Product and Solutions
2.16.4 Vetter Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.16.5 Vetter Recent Developments and Future Plans
2.17 Curia
2.17.1 Curia Details
2.17.2 Curia Major Business
2.17.3 Curia Full-Service CDMO Product and Solutions
2.17.4 Curia Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.17.5 Curia Recent Developments and Future Plans
2.18 Aenova
2.18.1 Aenova Details
2.18.2 Aenova Major Business
2.18.3 Aenova Full-Service CDMO Product and Solutions
2.18.4 Aenova Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.18.5 Aenova Recent Developments and Future Plans
2.19 Porton
2.19.1 Porton Details
2.19.2 Porton Major Business
2.19.3 Porton Full-Service CDMO Product and Solutions
2.19.4 Porton Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.19.5 Porton Recent Developments and Future Plans
2.20 Piramal
2.20.1 Piramal Details
2.20.2 Piramal Major Business
2.20.3 Piramal Full-Service CDMO Product and Solutions
2.20.4 Piramal Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.20.5 Piramal Recent Developments and Future Plans
2.21 Strides Pharma
2.21.1 Strides Pharma Details
2.21.2 Strides Pharma Major Business
2.21.3 Strides Pharma Full-Service CDMO Product and Solutions
2.21.4 Strides Pharma Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.21.5 Strides Pharma Recent Developments and Future Plans
2.22 NextPharma
2.22.1 NextPharma Details
2.22.2 NextPharma Major Business
2.22.3 NextPharma Full-Service CDMO Product and Solutions
2.22.4 NextPharma Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.22.5 NextPharma Recent Developments and Future Plans
2.23 Famar
2.23.1 Famar Details
2.23.2 Famar Major Business
2.23.3 Famar Full-Service CDMO Product and Solutions
2.23.4 Famar Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.23.5 Famar Recent Developments and Future Plans
2.24 Jubilant
2.24.1 Jubilant Details
2.24.2 Jubilant Major Business
2.24.3 Jubilant Full-Service CDMO Product and Solutions
2.24.4 Jubilant Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.24.5 Jubilant Recent Developments and Future Plans
2.25 Alcami
2.25.1 Alcami Details
2.25.2 Alcami Major Business
2.25.3 Alcami Full-Service CDMO Product and Solutions
2.25.4 Alcami Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.25.5 Alcami Recent Developments and Future Plans
2.26 Euroapi
2.26.1 Euroapi Details
2.26.2 Euroapi Major Business
2.26.3 Euroapi Full-Service CDMO Product and Solutions
2.26.4 Euroapi Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.26.5 Euroapi Recent Developments and Future Plans
2.27 Eurofins
2.27.1 Eurofins Details
2.27.2 Eurofins Major Business
2.27.3 Eurofins Full-Service CDMO Product and Solutions
2.27.4 Eurofins Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.27.5 Eurofins Recent Developments and Future Plans
2.28 Avid Bioservices
2.28.1 Avid Bioservices Details
2.28.2 Avid Bioservices Major Business
2.28.3 Avid Bioservices Full-Service CDMO Product and Solutions
2.28.4 Avid Bioservices Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.28.5 Avid Bioservices Recent Developments and Future Plans
2.29 BioVectra
2.29.1 BioVectra Details
2.29.2 BioVectra Major Business
2.29.3 BioVectra Full-Service CDMO Product and Solutions
2.29.4 BioVectra Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.29.5 BioVectra Recent Developments and Future Plans
2.30 CPL
2.30.1 CPL Details
2.30.2 CPL Major Business
2.30.3 CPL Full-Service CDMO Product and Solutions
2.30.4 CPL Full-Service CDMO Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.30.5 CPL Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Full-Service CDMO Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Full-Service CDMO by Company Revenue
3.2.2 Top 3 Full-Service CDMO Players 麻豆原创 Share in 2023
3.2.3 Top 6 Full-Service CDMO Players 麻豆原创 Share in 2023
3.3 Full-Service CDMO 麻豆原创: Overall Company Footprint Analysis
3.3.1 Full-Service CDMO 麻豆原创: Region Footprint
3.3.2 Full-Service CDMO 麻豆原创: Company Product Type Footprint
3.3.3 Full-Service CDMO 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Full-Service CDMO Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Full-Service CDMO 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Full-Service CDMO Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Full-Service CDMO 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Full-Service CDMO Consumption Value by Type (2019-2030)
6.2 North America Full-Service CDMO 麻豆原创 Size by Application (2019-2030)
6.3 North America Full-Service CDMO 麻豆原创 Size by Country
6.3.1 North America Full-Service CDMO Consumption Value by Country (2019-2030)
6.3.2 United States Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Full-Service CDMO Consumption Value by Type (2019-2030)
7.2 Europe Full-Service CDMO Consumption Value by Application (2019-2030)
7.3 Europe Full-Service CDMO 麻豆原创 Size by Country
7.3.1 Europe Full-Service CDMO Consumption Value by Country (2019-2030)
7.3.2 Germany Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Full-Service CDMO Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Full-Service CDMO Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Full-Service CDMO 麻豆原创 Size by Region
8.3.1 Asia-Pacific Full-Service CDMO Consumption Value by Region (2019-2030)
8.3.2 China Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Full-Service CDMO Consumption Value by Type (2019-2030)
9.2 South America Full-Service CDMO Consumption Value by Application (2019-2030)
9.3 South America Full-Service CDMO 麻豆原创 Size by Country
9.3.1 South America Full-Service CDMO Consumption Value by Country (2019-2030)
9.3.2 Brazil Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Full-Service CDMO Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Full-Service CDMO Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Full-Service CDMO 麻豆原创 Size by Country
10.3.1 Middle East & Africa Full-Service CDMO Consumption Value by Country (2019-2030)
10.3.2 Turkey Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Full-Service CDMO 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Full-Service CDMO 麻豆原创 Drivers
11.2 Full-Service CDMO 麻豆原创 Restraints
11.3 Full-Service CDMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Full-Service CDMO Industry Chain
12.2 Full-Service CDMO Upstream Analysis
12.3 Full-Service CDMO Midstream Analysis
12.4 Full-Service CDMO Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
听
听
*If Applicable.
